BNTXBioNTech SE

Nasdaq biontech.de


$ 86.03 $ -0.54 (-0.62 %)    

Wednesday, 31-Jul-2024 15:59:36 EDT
QQQ $ 473.02 $ 13.54 (2.96 %)
DIA $ 408.46 $ 1.08 (0.27 %)
SPY $ 551.56 $ 8.81 (1.63 %)
TLT $ 94.83 $ 0.96 (1.02 %)
GLD $ 226.56 $ 4.03 (1.81 %)
$ 86.2
$ 85.80 x 100
-- x --
-- - --
$ 78.02 - $ 125.83
401,766
na
20.49M
$ 0.07
$ 0.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biontech-reports-topline-data-from-ongoing-phase-2-clinical-trial-for-mrna-immunotherapy-candidate-bnt111-for-advanced-melanoma-trial-met-its-primary-efficacy-outcome-measure

The Phase 2 trial will continue as planned to further assess the secondary endpoints, which were not mature at the time of the ...

 european-commission-faces-court-criticism-over-covid-vaccine-contract-transparency-ahead-of-vote-on-ursula-von-der-leyens-reappointment

European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implication...

Core News & Articles

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First...

 gsk-buys-full-rights-to-investigational-covid-19-and-influenza-vaccines-from-curevac-for-around-15b

GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...

 london-high-court-ruling-fuels-pfizer-and-moderna-legal-dispute-over-covid-19-vaccine-patents

Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Cour...

 abbviegenmabs-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expansion-opportunities-underway

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...

Core News & Articles

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months ...

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

 gamestop-and-first-solar-were-among-the-10-biggest-large-cap-losers-last-week-june-16-june-22-are-these-in-your-portfolio

10 worst-performing large-cap stocks last week: GME, ENPH, ALB, BNTX, ALGN, FLSR, BALL, MBLY, BLD, JBL. Are they in your portfo...

 covid-19-pharma-stars-continue-their-quest-to-set-new-standards-in-cancer-treatment

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...

 why-is-pfizer-partner-biontech-stock-trading-lower-on-monday

BioNTech partner MediLink Therapeutics faces a partial clinical hold from the FDA on the Phase 1 trial of BNT326/YL202 for adva...

 biontech-partner-medilink-therapeutics-says-fda-has-placed-partial-clinical-hold-on-phase-1-trial-of-bnt326yl202-for-heavily-pre-treated-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-or-hrher2-negative-breast-cancer-6k

The partial hold affects the enrollment of new patients in the trial in the U.S.  The FDA has shared with MediLink concerns th...

Core News & Articles

- Reuters

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

 moderna-seeks-fda-approval-for-updated-covid-19-shot-for-upcoming-season

Moderna has submitted an FDA application for its 2024-2025 Spikevax formula, targeting the prevalent SARS-CoV-2 variant JN.1.

Core News & Articles

- Reuters

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION